For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 3,955 | 5,116 | ||
| General and administrative | 7,905 | 40,276 | ||
| Total operating expenses | 11,860 | 45,392 | ||
| Operating loss | -11,860 | -45,392 | ||
| Interest income | 1,167 | 1,214 | ||
| Other income (loss), net | -114 | -46 | ||
| Gain from change in fair value of warrant liabilities | 0 | 0 | ||
| Net income (loss) | -10,807 | -44,224 | ||
| Adjustment for change in fair value of warrant liabilities | 0 | 0 | ||
| Adjusted numerator, diluted | -10,807 | -44,224 | ||
| Basic EPS | -0.22 | -0.92 | ||
| Diluted EPS | -0.22 | -0.92 | ||
| Basic Average Shares | 48,308,000 | 48,308,000 | ||
| Diluted Average Shares | 48,308,000 | 48,308,000 | ||
CASSAVA SCIENCES INC (SAVA)
CASSAVA SCIENCES INC (SAVA)